Exp Ther Med 11: 49-56, 2016; DOI: 10.3892/etm.2015.2860
Subsequently to the publication of the above article, an interested reader drew to our attention that the article describes the use of the drug acetazolamide for IgA nephropathy on a number of occasions in the text, whereas the references refer to the drug azathioprine. The authors have confirmed that, owing to an oversight on their part, all the references to “acetazolamide” in their paper (abbreviated as ‘AZA’) should have been written as “azathioprine” (first, in the Abstract on p. 49, line 18, and subsequently in the legends of Table I and Figs. 2 and 7). Given the serious nature of this error, please note that the drug name for ‘AZA’ has been corrected in the article itself, and an updated version of the paper has been uploaded to PubMed Central. Furthermore, the abbreviation for leflunomide should have been written throughout the paper as “LEF”, not as “LET”.
The authors deeply regret that these errors were allowed to enter into their text, and were not corrected prior to publication. The authors also apologize to the readership for any inconvenience caused.